MELBOURNE Australia, 1 May, 2017: AdAlta Limited (ASX:1AD), the biotechnology Company advancing its lead i-body candidate towards clinical development today announced the release of its Idiopathic Pulmonary Fibrosis (IPF) Overview Document. The document provides background into IPF pathology, current treatments, the market landscape as well as the progress of AdAlta’s lead i-body towards the clinic.
IPF is a lung disease the affects approximately 10,000 Australians and approximately 300,000 worldwide, with 50% of people dying within 2 to 3 years of diagnosis. Idiopathic pulmonary fibrosis causes scarring and stiffening of the lungs that restricts breathing and oxygen exchange. Currently approved therapies, Nintedanib and Pirfenidone, slow disease progression but do not act as a cure and are also associated with significant side effects.
AdAlta is developing its lead i-body candidate, AD-114, for the treatment of IPF and received Orphan Drug Designation from the United States Food and Drug Administration in January 2017. AD-114 has strong pre-clinical results for IPF, demonstrating both anti-fibrotic and anti-inflammatory activity in human lung tissue and greater efficacy than existing approved IPF drugs.
Chief Executive Officer Sam Cobb said “AdAlta is moving AD-114 towards the clinic to address the clear unmet medical need that exists for Idiopathic Pulmonary Fibrosis”
The IPF overview document is available on the AdAlta website along with a video presentation from AdAlta’s fibrosis briefing in February by Dr Glen Westall, IPF respiratory physician at The Alfred Hospital, Melbourne and AdAlta collaborator.
Notes to Editors
AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.
I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.
We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.
AdAlta is developing its lead i-body candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.
The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.
Further information can be found at: www.adalta.com.au.
For more information, please contact:
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159